Simplifying Testing, Amplifying Access

SalivaDirect, Inc. (SDI) is advancing the use of saliva-based testing as a readily-deployable, sensitive, patient-friendly option that increases access to affordable and equitable infectious disease testing.

Since
1950
Labs Designated
150 +
Tests Administered
5 mil+

Save the Date

SalivaDirect, Inc. is thrilled to announce that our annual conference for 2025 will be held virtually! Mark your calendars for June 3-6 to hear from top experts in diagnostics on a GLOBAL scale.

SalivaDirect, Inc. Global Conference Image

SDI's March Webinar

SDI is pleased to host our next Diagnostics Webinar on Tuesday, March 4th, from 11 am-12 pm EST.

Image of a laptop in a webinar

Shape the Future of Diagnostics

Join our community of supporters today to be part of making diagnostic testing more accessible for all.

7

Stay up to date.

Subscribe to Our Newsletter

The SalivaDirect™ test is a cutting-edge, non-invasive COVID-19 diagnostic test that detects SARS-CoV-2 RNA from saliva samples. 

The SalivaDirect™ Test for COVID-19 is:

Non-Invasive and Self-Collectible

Saliva collection is non-invasive, reducing patient aversion to testing. It is readily self-collected, which can reduce the risk of viral transmission to healthcare workers.

Flexible and Scalable

The flexible nature of the SalivaDirect™ protocol reduces barriers to entry for labs by allowing them to use their existing reagent and instrument suppliers.

Cost-Efficient

Our test does not require swabs or preservative media in saliva collection devices, reducing the cost of the test kit itself. Utilizing a nucleic acid extraction-free approach reduces the cost of reagents and labor, as well as improves a laboratory’s turnaround time.

Authorized for Emergency Use by the FDA

The SalivaDirect™ protocol for SARS-CoV-2 has been authorized for Emergency Use by the U.S. Food and Drug Administration, ensuring it meets the agency’s rigorous performance standards for in vitro diagnostics. It has also been independently validated in 15+ countries around the globe. We anticipate a submission for De Novo authorization from the U.S. Food and Drug Administration in 2025.

Our Funding Partners

Venturewell Logo
The Rockefeller Foundation Logo
Fast Grants, COVID-19 Research Funding Logo
balvi.io logo
NIH Logo
Flambeau RapidX Logo

News and Updates

July 12, 2024

Mobile Lab Helps Yale Pathology Establish Relationships, Build Trust With Community

Photo of Anne Wyllie in Lab

July 11, 2024

Saliva-Based Tests Offer an Alternative to Nasal Swabbing

Image of SDI Team Members, Russ and Yasmine

November 16, 2023

Where Activism Meets Science: Spotlight on Russell Thomas

Image of team in front of mobile lab

April 24, 2023

High-Tech Mobile Lab-in-a-Van Will Bring Needed Testing to Underserved Communities

January 27, 2022

New Partnership Between CT, Yale to Expand Saliva-Based COVID Testing at 2 New Haven Locations

August 15, 2020

Saliva-Based COVID-19 Test Developed by Yale Scientists Authorized for Emergency Use by FDA

Skip to content